Lineage Cell Therapeutics, Inc. (LCTX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Lineage Cell Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Lineage Cell Therapeutics, Inc. (LCTX) has returned -5.39% so far this year and 249.87% over the past 12 months. Over the last ten years, LCTX has returned -4.69% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since Mar 6, 1992, LCTX's average daily return is +0.15%, while the average monthly return is +2.05%. At this rate, your investment would double in approximately 2.8 years.

Historically, 43% of months were positive and 57% were negative. The best month was Aug 2008 with a return of +152.9%, while the worst month was Aug 2005 at -38.8%. The longest winning streak lasted 9 consecutive months, and the longest losing streak was 11 months.

On a daily basis, LCTX closed higher 41% of trading days. The best single day was Nov 15, 2002 with a return of +95.9%, while the worst single day was Jul 31, 2006 at -35.9%.

Lineage Cell Therapeutics, Inc. has an annualized alpha of 32.19%, beta of 0.89, and R² of 0.03 versus S&P 500 Index. Calculated based on daily prices since March 09, 1992.

• This stock participated in 146.60% of S&P 500 Index downside but only 104.19% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.03 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

LCTX ranks 95 for risk / return — in the top 95% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Lineage Cell Therapeutics, Inc. (LCTX) and compare them to a chosen benchmark (S&P 500 Index).

Lineage Cell Therapeutics, Inc. provided a 0.00% dividend yield over the last twelve months, with an annual payout of $0.00 per share.

The table displays the monthly dividend distributions for Lineage Cell Therapeutics, Inc.. The dividends shown in the table have been adjusted to account for any splits that may have occurred.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Lineage Cell Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Lineage Cell Therapeutics, Inc. was 99.31%, occurring on Aug 28, 2006. The portfolio has not yet recovered.

The current Lineage Cell Therapeutics, Inc. drawdown is 91.91%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Lineage Cell Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Lineage Cell Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.